Novartis says it's not interested in merging with another Big Pharma player--but CEO Daniel Vasella (photo [1]) still won't comment on a rumored takeover [2] of German rival Bayer.
Vasella told a French newspaper that a merger isn't the answer to the company's skyrocketing R&D costs and less-than-skyrocketing revenues. But when asked point-blank about Bayer, he clammed up. Some stock analysts have pooh-poohed the notion of Novartis snapping up Bayer. Others, however, helped fuel the rumors, which have died down a bit lately. Vasella's "no comment" just may stir them up again.Â
- read the coverage [3] from Forbes
Related Articles:
Rumor Mill: Novartis may bid for Bayer. Report [2]
Cash-rich Novartis CEO mulls biotech buyouts. Report [4]
Bayer plans to beef up biotech pipeline. Report [5]
Novartis CEO critiques U.S. healthcare. Report [6]
Links:
[1] http://www.fiercebiotech.com/pages/novartis-ceo-daniel-vasella
[2] http://www.fiercepharma.com/story/rumor-mill-novartis-may-bid-bayer/2007-08-16
[3] http://www.forbes.com/markets/feeds/afx/2007/09/17/afx4123070.html
[4] http://www.fiercebiotech.com/story/cash-rich-novartis-ceo-mulls-biotech-buyouts/2007-04-16
[5] http://www.fiercebiotech.com/story/bayer-plans-to-beef-up-biotech-pipeline/2007-01-02
[6] http://www.fiercepharma.com/story/also-noted-aventis-settles-fraud-claims-novartis-ceo-critiques-u-s-healthcare/2007-09-10?utm_medium=rss&utm_source=rss